- Home
- ONCT vs NVVE Comparison
ONCT vs NVVE Comparison
Compare ONCT & NVVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ONCT
- NVVE
- Stock Information
- Founded
- ONCT N/A
- NVVE 1996
- Country
- ONCT United States
- NVVE United States
- Employees
- ONCT N/A
- NVVE N/A
- Industry
- ONCT Biotechnology: Pharmaceutical Preparations
- NVVE Oil Refining/Marketing
- Sector
- ONCT Health Care
- NVVE Energy
- Exchange
- ONCT Nasdaq
- NVVE Nasdaq
- Market Cap
- ONCT 4.3M
- NVVE 3.5M
- IPO Year
- ONCT N/A
- NVVE N/A
- Fundamental
- Price
- ONCT $1.13
- NVVE $3.40
- Analyst Decision
- ONCT Buy
- NVVE
- Analyst Count
- ONCT 3
- NVVE 0
- Target Price
- ONCT $10.00
- NVVE N/A
- AVG Volume (30 Days)
- ONCT 156.9K
- NVVE 27.4K
- Earning Date
- ONCT 11-06-2024
- NVVE 11-12-2024
- Dividend Yield
- ONCT N/A
- NVVE N/A
- EPS Growth
- ONCT N/A
- NVVE N/A
- EPS
- ONCT N/A
- NVVE N/A
- Revenue
- ONCT $2,161,000.00
- NVVE $5,144,831.00
- Revenue This Year
- ONCT $113.76
- NVVE $200.61
- Revenue Next Year
- ONCT N/A
- NVVE $109.43
- P/E Ratio
- ONCT N/A
- NVVE N/A
- Revenue Growth
- ONCT 227.92
- NVVE N/A
- 52 Week Low
- ONCT $1.03
- NVVE $3.22
- 52 Week High
- ONCT $13.20
- NVVE $86.00
- Technical
- Relative Strength Index (RSI)
- ONCT 37.09
- NVVE 38.98
- Support Level
- ONCT $1.03
- NVVE $3.22
- Resistance Level
- ONCT $1.30
- NVVE $4.02
- Average True Range (ATR)
- ONCT 0.19
- NVVE 0.29
- MACD
- ONCT -0.01
- NVVE 0.02
- Stochastic Oscillator
- ONCT 13.70
- NVVE 22.50
About ONCT Oncternal Therapeutics Inc.
Oncternal Therapeutics Inc is a clinical-stage oncology company developing first-in-class, novel therapies that target a broad spectrum of cancers with a large unmet medical need. The Company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to ROR1 (Receptor-tyrosine kinase-like Orphan Receptor 1), and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoprotein. The Company is also developing ONCT-808, a CAR-T (chimeric antigen receptor T-cells) product candidate that target ROR1, and ONCT-534, a dual-action androgen receptor inhibitor product candidate for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. The Company has one operating segment in the United States.
About NVVE Nuvve Holding Corp.
Nuvve Holding Corp is accelerating the electrification of transportation through its proprietary vehicle-to-grid (V2G) technology. It helps to support the integration of renewable energy sources, including solar and wind. Its Grid Integrated Vehicle (GIV) platform is refueling the next generation of electric vehicle fleets through bidirectional charging solutions. It has a geographic presence in the United States, the United Kingdom, and Denmark, of which it generates the majority of its revenue in the United States.